PMID- 17643399
OWN - NLM
STAT- MEDLINE
DCOM- 20080227
LR  - 20191210
IS  - 1873-2402 (Electronic)
IS  - 0006-3223 (Linking)
VI  - 63
IP  - 2
DP  - 2008 Jan 15
TI  - Monoamine oxidase inhibition dramatically prolongs the duration of nicotine 
      withdrawal-induced place aversion.
PG  - 158-63
AB  - BACKGROUND: Long-lasting effects of withdrawal from nicotine are hypothesized to 
      contribute to relapse and persistence of tobacco habits, and significant evidence 
      supports a role of monoamine oxidase inhibitors (MAOI) contained in cigarette 
      smoke as potent modulators of the rewarding effects of tobacco. METHODS: With 
      quantification of somatic signs of withdrawal and the place aversion conditioning 
      paradigm, we assessed the effects of MAOI pretreatment on both somatic and 
      aversive motivational components of mecamylamine-induced nicotine withdrawal in 
      rats rendered dependent on nicotine by the subcutaneous implantation of osmotic 
      minipumps (vehicle or nicotine tartrate 9 mg/kg/day). RESULTS: In 
      nicotine-infused rats, mecamylamine induced a place aversion that lasted 6 weeks. 
      When nicotine-infused rats were also treated with a MAOI, mecamylamine-induced 
      conditioned place aversion persisted for at least 8 months of abstinence. The 
      MAOI treatment slightly decreased ratings of somatic signs induced by 
      mecamylamine administration but had no effect on the threshold or the magnitude 
      of mecamylamine-induced conditioned place aversion. CONCLUSIONS: These results 
      show that MAOI pretreatment induces a long-lasting conditioned placed aversion 
      associated with nicotine withdrawal, possibly through a potentiation of learning 
      and memory process, and provides some indications on protracted abstinence that 
      might be useful for delineating the neurobiological substrate of relapse.
FAU - Guillem, Karine
AU  - Guillem K
AD  - Laboratoire de Neuropsychobiologie des Desadaptations UMR CNRS 5541, Universite 
      de Bordeaux 2, Bordeaux, France. guillemk@sas.upenn.edu
FAU - Vouillac, Caroline
AU  - Vouillac C
FAU - Koob, George F
AU  - Koob GF
FAU - Cador, Martine
AU  - Cador M
FAU - Stinus, Luis
AU  - Stinus L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070723
PL  - United States
TA  - Biol Psychiatry
JT  - Biological psychiatry
JID - 0213264
RN  - 0 (Monoamine Oxidase Inhibitors)
RN  - 0 (Nicotinic Agonists)
RN  - 0 (Nicotinic Antagonists)
RN  - 6EE945D3OK (Mecamylamine)
RN  - 6M3C89ZY6R (Nicotine)
RN  - EC 1.4.3.4 (Monoamine Oxidase)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Avoidance Learning/drug effects/*physiology
MH  - Behavior, Animal/drug effects
MH  - Conditioning, Psychological/drug effects/*physiology
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Routes
MH  - Drug Interactions
MH  - Male
MH  - Mecamylamine/pharmacology
MH  - Monoamine Oxidase/*metabolism
MH  - Monoamine Oxidase Inhibitors/pharmacology
MH  - Nicotine/adverse effects
MH  - Nicotinic Agonists/adverse effects
MH  - Nicotinic Antagonists/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Substance Withdrawal Syndrome/etiology/physiopathology/*psychology
EDAT- 2007/07/24 09:00
MHDA- 2008/02/28 09:00
CRDT- 2007/07/24 09:00
PHST- 2006/11/07 00:00 [received]
PHST- 2007/03/29 00:00 [revised]
PHST- 2007/04/21 00:00 [accepted]
PHST- 2007/07/24 09:00 [pubmed]
PHST- 2008/02/28 09:00 [medline]
PHST- 2007/07/24 09:00 [entrez]
AID - S0006-3223(07)00399-X [pii]
AID - 10.1016/j.biopsych.2007.04.029 [doi]
PST - ppublish
SO  - Biol Psychiatry. 2008 Jan 15;63(2):158-63. doi: 10.1016/j.biopsych.2007.04.029. 
      Epub 2007 Jul 23.